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Persistent B cell responses in mucosal tissues are crucial to control infection against 
sexually transmitted pathogens like human immunodeficiency virus 1 (HIV-1). The genital 
tract is a major site of infection by HIV. Sublingual (SL) immunization in mice was previously 
shown to generate HIV-specific B cell immunity that disseminates to the genital tract. We 
report here the immunogenicity in female cynomolgus macaques of a SL vaccine based 
on a modified gp41 polypeptide coupled to the cholera toxin B subunit designed to 
expose hidden epitopes and to improve mucosal retention. Combined SL/intramuscular 
(IM) immunization with such mucoadhesive gp41-based vaccine elicited mucosal HIV-
specific IgG and IgA antibodies more efficiently than IM immunization alone. This strategy 
increased the number and duration of gp41-specific IgA secreting cells. Importantly, 
combined immunization improved the generation of functional antibodies 3  months 
after vaccination as detected in HIV-neutralizing assays. Therefore, SL immunization 
represents a promising vaccine strategy to block HIV-1 transmission.
Keywords: sublingual immunization, mucosal antibodies, B memory response, neutralization, hiV, trimeric gp41, 
cholera toxin B subunit
inTrODUcTiOn
The genital tract represents a major site of human immunodeficiency virus (HIV)-1 transmission 
(1, 2). Vaccination protocols aiming at developing systemic IgG antibody or cytotoxic T  cell 
responses were not effective or only partly protective against HIV-1 heterosexual infection, 
respectively (3, 4). The reasons why these vaccines failed to be protective still remain to be fully 
established. One can expect that mucosal antibody responses could play a role in protection. 
Indeed, HIV-specific secretory IgA and IgG were detected in the cervico-vaginal secretions of 
HIV-exposed uninfected individuals. Such antibodies were described to exert HIV-neutralizing 
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activity or to block HIV transcytosis through an artificial 
epithelium (5–7). The HIV-1 glycoprotein gp41 undergoes 
conformational changes leading to membrane fusion and viral 
entry. It is one target of neutralizing or blocking antibodies. 
Therefore, the development of vaccines that induce mucosal B 
cell immunity against selected epitopes of gp41 should protect 
against HIV-1 infection.
Mucosal immunization, unlike parenteral immunization, 
favors the generation of B and T cell responses both at the site 
of mucosal immunization and in distant mucosae (8). Vaginal 
immunization was shown to induce IgA and IgG antibody-
secreting cells in the vagina as well as cervico-vaginal and serum 
antibodies (9–11). Nasal immunization gave rise to robust IgA 
and IgG antibody responses in macaque and human genital 
tracts (10, 12). Nevertheless, there is a risk of antigen passage 
through the brain barrier after nasal vaccination as experienced 
with a toxin-based non-living influenza vaccine that can limit 
the development of nasal subunit vaccines (13). More recently, 
the sublingual (SL) route for delivering vaccines was shown to 
generate broadly disseminated mucosal and systemic immune 
responses (14, 15). Notably, SL immunization in mice was as 
potent as vaginal immunization for the induction of IgA and 
IgG antibody and cytotoxic T cell responses in the female genital 
tract, whereas parenteral immunization did not. It provided 
protection against genital challenge with HPV pseudovirions 
(11, 16). Moreover, recent prime-boost vaccine strategies com-
bining mucosal (either nasal or SL) and systemic immunizations 
were beneficial to generate protection in macaques against a 
challenge by SHIV (17) or in mice against Chlamydia genital 
shedding (18).
Mucosal immunization with non-replicative antigens 
requires the use of adjuvants and delivery systems in order to 
break mucosal tolerance and to facilitate the uptake of immu-
nogens (19). The cholera toxin B subunit (CTB) binds to GM1 
gangliosides expressed by all nucleated cells and constitutes a 
good antigen-delivery vector for covalently linked proteins and 
polysaccharides (20). Intravaginal or SL application of an antigen 
covalently coupled to CTB in mice was shown to generate vaginal 
B and T cell responses (16, 21). The potential of SL immuniza-
tion in macaques and in humans remains to be established. In 
the current study, we investigated the immunogenicity in female 
cynomolgus macaques of a SL prime/intramuscular (IM) boost 
HIV gp41-based vaccine designed to expose hidden epitopes.
MaTerials anD MeThODs
Vaccine
The trimeric HIV-1 gp41-derived polypeptide (mgp41) was 
produced by PX’therapeutics (Grenoble, France) and charac-
terized by biophysical analyses as described in Supplementary 
Material. Several mgp41 amine residues were substituted with 
sulfhydryl groups using Traut’s reagent (Piercenet, Rockfort, 
IL, USA) and then coupled to CTB (Crucell AB, Stockholm, 
Sweden) using the sulfosuccinimidyl 4-[p-maleimidophenyl]
butyrate crosslinker (Piercenet). The CTB-mgp41 conjugate was 
purified by ultracentrifugation on AMICON filters and its purity 
checked by migration on SDS-PAGE gel. Its biological activity 
and the CTB:mgp41 ratio were measured by solid phase ELISA 
using GM1 gangliosides as capture system and antibodies to CTB 
or mgp41 for detection. Cholera toxin (CT) from List Biologicals 
laboratories (USA) was used as adjuvant for SL immunizations 
and Aluminum hydroxide (Sanofi-Pasteur, Lyon, France) as 
adjuvant for IL immunizations.
study Design
Eighteen adult female cynomolgus macaques (Macaca fascicu-
laris) from Mauritius were housed within CEA animal facilities 
(Fontenay-aux-Roses, France) according to French national 
regulations and under the supervision of national veterinary 
inspectors (CEA Permit Number A 92-032-02). The CEA com-
plies with the Standards for Human Care and Use of Laboratory 
Animals of the Office for Laboratory Animal Welfare (OLAW, 
USA) under OLAW Assurance number #A5826-01. This study 
was approved and accredited under statement number A10-053 
by the ethics committee “Comité d’Ethique en Expérimentation 
Animale du CEA” registered under number 44 by the French 
Ministry of Research. Animals weighing between 3 and 6 kg, 
seronegative for SIV, STLV, filovirus, HBV, herpes B, and mea-
sles and genotyped for Class I and Class II MHC alleles were 
used. They were equally distributed between groups based on 
their genotype (n = 6 per group). Animals were sedated with 
ketamine chlorhydrate (Rhone-Merieux, Lyon, France) for 
1 h. Group 1 received five SL immunizations with CTB-mgp41 
(100 μg/dose of mgp41 antigen at W0, 4, and 12 and 50 μg/dose 
at W8 and 20) with CT (10 μg/dose). Group 2 received three SL 
immunizations with CTB-mgp41 and CT (SL priming) at W0, 4, 
and 8 similarly to group 1 followed by IM boosts with 100 µg of 
mgp41 in Alum (500 μg/dose) at W12 and 20. Group 3 received 
a SL priming with CT alone (10 µg) at W0, 4, and 8 followed by 
IM boosts with 100 µg of mgp41 in Alum (500 μg/dose) at W12, 
20, and 28. The SL vaccine was applied in a 500 µL volume of 
PBS under the tongue of sedated animals with their head bend-
ing forward to avoid leakage of excess of vaccine and was then 
rinsed with PBS 15 min later in order to avoid swallowing. For 
intramuscular immunizations, a 500 µL volume was injected in 
the right thigh for W12, the left thigh for W20, and the right 
thigh for W28.
Fluid harvesting
Blood, vaginal, and rectal washes were collected for antibody 
analysis by ELISA (W0, W6, W10, W14, W22, W24, and W28). 
Vaginal and rectal secretions were collected using Weck-cel™ 
sponges pre-moistened with 100 µL of PBS in presence of pro-
tease inhibitors as described previously (22).
Measurement of specific antibodies
Fluids were assayed for mgp41-specific IgA and IgG antibodies 
by a two-step amplified ELISA using biotin-conjugated goat anti-
human IgG or IgA antibodies (Southern Biotech, Birmingham, 
AL, USA) and HRP-conjugated avidin (Sigma-Aldrich, 
St. Quentin Fallavier, France). Solid-phase bound HRP activity 
was monitored spectrophotometrically after addition of enzyme 
substrate. The endpoint titer was the reciprocal of the sample 
dilution giving an absorbance at least equal to threefold that of 
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background [corresponding pre-immune sample at the lowest 
dilution (1/50 for sera and 1/3 for mucosal samples)].
cell isolation
Peripheral blood mononuclear cells (PBMCs) were isolated from 
blood 5 days after the priming (W9) and the boost (W21 for group 
1 and 2 or W29 for group 3), 4 weeks after the last immunization 
(W24, groups 1 and 2 or W32, group 3), and 3 months after the 
last immunization (W32, groups 1 and 2 or W40, group 3) and 
assessed for antibody-secreting cells (ASCs) by B cell ELISPOT 
assay. Macaques were sacrificed 3 months after the last immuni-
zation (W33, groups 1 and 2 and W41, group 3) and rectal and 
vaginal mononuclear cells (MNCs) were prepared by enzymatic 
digestion of tissues with collagenase II (0.3  mg/mL) in the 
presence of trypsin inhibitor (0.1 mg/mL) (Sigma-Aldrich) and 
DNase I (0.1 mg/mL) (Roche) in RPMI medium supplemented 
with 3% FBS, 25 mM Hepes, antibiotics and Fungizon® according 
to supplier’s recommendations (Invitrogen, Saint Aubin, France). 
Bone marrow (BM) MNC from iliac crest or from humerus were 
isolated using Ficoll density-gradient centrifugation (MSL2000, 
Eurobio, Les Ulis, France). PBMC and tissue-derived MNC 
collected 1 or 3  months after immunization were stimulated 
in vitro for 6 days with Pokeweed Mitogen (PWM, 1 µg/mL) and 
Staphylococcus aureus Cowan strain (SAC, 0.1 µg/mL) (Sigma-
Aldrich) before ASC enumeration.
B cell elispot assay
Peripheral blood mononuclear cell and MNC from vagina and 
rectum were assayed for mgp41-specific ASC using an amplified 
B ELISPOT assay as described (23). Briefly, graded numbers 
of cells (between 1 × 105 and 8 × 105) were incubated for 16 h 
at 37°C in nitrocellulose-bottom 96-well plates coated with 
mgp41 (5 µg/mL) for detection of mgp41-specific ASC or with 
mouse anti-human kappa and lambda antibodies (5  µg/mL) 
(Southern Biotech, Birmingham, AL, USA) for detection of 
total ASC. The antibodies produced were detected by stepwise 
incubations with biotin-conjugated goat anti-human IgG or IgA 
(KPL, Gaithersburg, MD, USA), avidin-conjugated peroxidase 
(Sigma-Aldrich), and AEC-H2O2 chromogenic peroxidase 
substrate (Sigma-Aldrich). Spots were enumerated using CTL 
immunospot analyzer (Bonn, Germany).
Flow cytometry
Mononuclear cells were incubated with fluorescent monoclonal 
antibodies against surface markers in order to identify B cell 
subsets. Antibodies from BD Biosciences used: anti-CD45 
(clone D058-1283), anti-CD3 (clone SP34-2), anti-HLA-DR 
(clone L243), anti-CD20 (clone 2H7), as well as anti-CD27 (clone 
M-T271, Miltenyi) and anti-IgD (rabbit polyclonal, AbDserotec). 
Cells were analyzed on BD LSRII FACS analyzer and Diva 
Software (BD Biosciences).
immunostainings
Cryosections of SL mucosa were fixed with acetone before 
hematoxylin/eosin staining according to supplier’s instructions 
(Sigma-Aldrich) and analyzed using a fluorescence microscope 
DMD108 (Leica, Nanterre, France). Cryosections were stained 
with purified antibodies against HLA-DR-DP-DQ (clone 
CR3/473) and CD1a (clone O10) (Dako, Les Ulis, France) or cor-
responding isotype controls, revealed with donkey anti-mouse 
AlexaFluor 594 (Invitrogen), and analyzed with Zeiss LSM780 
confocal microscope (Marly Le Roi, France).
Virus neutralization assay
Neutralization assays were performed as described (24) using two 
standard reference strains as Env-pseudotyped viruses (SF162.
LS, tier 1 and QH0692.42, tier 2) to infect TZM-bl cells. The 50% 
inhibitory dose was defined as the sample dilution that caused a 
50% reduction in relative luminescence units (RLUs) (25).
statistical analyses
Statistical analyses were carried out with Graphpad prism ver-
sion 6.0 (La Jolla, CA, USA). Pairwise multiple comparisons of 
experimental groups were performed using the non-parametric 
Mann–Whitney U-test.
resUlTs
Vaccine characterization
A vaccine containing a gp41 polypeptide conjugated to the 
CTB mucoadhesive vector was designed to improve its SL 
delivery (Figure  1). We used a gp41 polypeptide including 
the gp41 amino acids M24 to S157 from the gp41 sequence of 
the BRU/LAI isolate in which several mutations were added 
(Figure 1A) (26). Mutations of seven residues were introduced 
in the gp41 loop region to increase its net charge and reduce its 
hydrophobicity, thus reducing the propensity to aggregation of 
the gp41 ectodomain (27). In addition, eight additional muta-
tions were made at the C-terminal helical region (CHR) to open 
the six-helix bundle structure and to expose hidden epitopes 
at the conserved N-terminal helical region (NHR). Dynamic 
light scattering analyses revealed that the mutated gp41 (called 
hereafter mgp41) was trimeric in solution. Circular dichroism 
measurements indicated that around 66% of the mgp41 structure 
was in alpha-helices and that its thermal stability was strongly 
reduced compared to the native gp41 ectodomain (Figure S1 in 
Supplementary Material) (28), suggesting a destabilization of the 
six-helix bundle. Accessibility of NHR epitopes was confirmed by 
the significant binding of an exogenous CHR peptide to mgp41 
(gp41 sequence 110-141) (29) (Figure S1 in Supplementary 
Material). The mgp41 polypeptide was chemically conjugated to 
CTB using a strategy allowing the coupling of one mgp41 per 
CTB pentamer as illustrated in Figure 1B.
Vaccine strategy in Macaques
The immunogenicity of the SL CTB-mgp41 vaccine was evalu-
ated in female cynomolgus macaques. Immunohistochemistry 
analysis confirmed that the macaque SL mucosa was an immuno-
competent tissue with a pluristratified epithelium underlined by 
a thin submucosa containing MHCII+ antigen-presenting cells, 
some of them being CD1a+ dendritic cells (DCs) (Figures 2A,B). 
We compared the efficacy of the SL route of vaccination to the 
IM immunization and to a combined strategy including SL 
priming followed by IM boost (SL/IM) to generate serum and 
FigUre 1 | Mgp41-cholera toxin B subunit (cTB) vaccine construct used for sublingual immunizations. (a) Linear sequence of the human 
immunodeficiency virus (HIV)-1 gp41 fragment including punctual mutations designed to increase antigen solubility under physiological conditions (highlighted in red) 
and to potentiate exposure of hidden conserved epitopes in gp41 (highlighted in cyan). (B) Schematic ribbon representation of one mutated gp41 polypeptide 
fragment in a trimeric form (mgp41) chemically linked to a pentamer of CTB used as mucosal antigen delivery vector as detailed in Section “Materials and Methods.” 
The picture was made using Swiss PDB viewer (30) using the model structures of the HIV gp41 ectodomain (PDB code 1IF3) (31) and the cholera toxin B-pentamer 
(PDB code 1CHB) (32). The spatial orientation of the C-terminal helical region helices of mgp41 was manually altered to indicate disruption of the six-helix bundle 
structure. Mutated residues in mgp41 are highlighted as sticks in one of the monomers. The locations of the immunodominant region and the 2F5 epitope region are 
also indicated on one of the gp41 monomers. Each polypeptide monomer is represented in different colors for clarity. The divalent cross-linker is represented with 
red sticks. The resulting subunit vaccine [called cholera toxin B subunit (CTB)-mgp41] contains one trimeric gp41 per CTB pentamer.
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mucosal IgG and IgA antibodies against mgp41. As illustrated 
in Figure  2C, six macaques (group 1, SL) were immunized 
sublingually with CTB-mgp41 together with CT used as mucosal 
adjuvant. Six macaques (group 2, SL/IM) received a SL priming 
similarly to group 1 followed by IM boosts. In order to evaluate 
the impact of the SL priming in the combined SL/IM vaccina-
tion, the six macaques from group 3 (IM) were primed with CT 
alone by SL immunization and received IM boosts with mgp41 
in Alum. Furthermore, macaques from group 3 received a third 
IM immunization in order to compare SL and SL/IM strategies to 
optimized conditions for IM vaccination.
sl Priming immunization improves 
antigen-specific antibody responses
To compare the potential of SL immunization to classical IM 
vaccination, we quantified the mgp41-specific antibodies of IgG 
FigUre 2 | Vaccination strategy. (a,B) Cryosections analyses of the macaque sublingual (SL) tissue. (a) Haematoxylin eosin staining of the SL mucosa 
from a control cynomolgus macaque. (B) SL distribution of MHCII+ cells (MHCII+, left panel) and CD1a+ cells (right panel) by immunofluorescence. Nuclei are 
stained with Dapi (blue color). E, epithelium; LP, lamina propria. (c) Female cynomolgus macaques were immunized at weeks (W) 0, 4, 8, 12, and 20 either 
with cholera toxin B subunit (CTB)-mgp41 together with cholera toxin (CT) (red arrowheads) or CT alone (orange arrowheads) by SL route or with mgp41 in 
alum by intramuscular (IM) route (blue arrowheads). Macaques from group 1 were immunized sublingually with CTB-mgp41 together with CT at the doses 
indicated in Section “Materials and Methods.” Macaques from group 2 received a SL priming immunization at W0, 4, and 8 similar to group 1 followed by an 
IM boost immunization with 100 µg of mgp41 in Alum at W12 and 20. Macaques from group 3 received a priming SL immunization with CT alone at W0, 4, 
and 8 followed by three IM boost immunizations (W12, 20, and 28). Black arrows correspond to sample collections. Vaginal, rectal secretions, and sera were 
collected throughout the protocol for antibody analysis by ELISA. Peripheral blood mononuclear cells (PBMCs) were prepared for B ELISPOT analysis from 
blood of pre-immune macaques, blood of immunized macaques collected 5 days after priming (W9), 5 days after boost (W21), and 3 months after boost 
(W32 or W40). Macaques were sacrificed 1 week later (W33 or W41) and PBMC as well as bone marrow cells were prepared for memory B cells analysis by 
flow cytometry.
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and IgA isotypes generated throughout the protocol. Antigen-
specific antibodies were measured in sera (Figure  3) and in 
vaginal and rectal washes (Figure 4) at the indicated time points. 
The macaques that received five SL immunizations had notable 
serum mgp41-specific IgG titers up to 2  months after the last 
immunization (Figure 3A, left panel; Figure 3B, upper panel). 
Serum mgp41-specific IgG titers reached a significant value after 
the third SL immunization but the titers did not increase with 
subsequent SL immunizations (Figure 3A, left panel), suggesting 
that repeated immunizations with 1-month intervals reduced 
antigen uptake. In contrast, boost IM immunizations in the SL/
IM strategy increased serum mgp41-specific IgG titers by around 
10-fold compared to SL immunization (Figure 3A). Interestingly, 
SL/IM immunization gave significantly higher mgp41-specific 
IgG antibody levels than the IM strategy 2 weeks and 1 month 
after the fifth immunization, indicating that SL priming potenti-
ated antibody responses (Figure 3A). No statistical differences in 
serum mgp41-specific IgA titers were detected between immuni-
zation groups (Figure 3).
Vaginal and rectal antibody levels induced by the differ-
ent vaccine strategies were low (Figure  4). All the macaques 
had mgp41-specific IgG in vaginal washes (Figure  4A), 
suggesting that these antibodies were produced systemically. 
Accordingly, rare mgp41-specific IgG ASCs were detected in 
the genital tract of macaques (data not shown). Interestingly, 
the SL/IM immunization induced significantly higher levels of 
gp41-specific IgG antibodies compared to the IM immuniza-
tion 2  weeks after the fourth and fifth immunizations both 
in the genital tract and the rectal mucosa (Figures  4A,C). 
Furthermore, mgp41-specific IgA antibodies were detected in 
the genital tract and in the rectal mucosa after SL and SL/IM 
vaccination, but not after IM immunization (Figures  4B,D). 
Of note, the individuals who developed vaginal responses were 
the same who developed rectal responses (data not shown). 
FigUre 3 | sl/iM combined immunization increases mgp41-specific igg antibody responses in serum. Macaques were immunized according to the 
study design detailed in Figure 2c. SL referred to group 1, SL/IM to group 2, and IM to group 3. Mgp41-specific IgG and IgA antibodies were detected in macaque 
sera at indicated time points (from week 0 to week 28) by ELISA. (a) Data represent the geometric means of endpoint titers measured at indicated time points for 
each immunization group (n = 6 per group). * and ** in graphs denote statistical differences between SL group or SL/IM group and IM group using the non-
parametric Mann–Whitney U-test, *p < 0.05 and **p < 0.005. (B) Graphs correspond to titers from individual sera (n = 6) at the indicated time points for each 
immunization group (group 1, left graph; group 2, middle graph; group 3, right graph).
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Furthermore, vaginal gp41-specific IgA antibodies detected in 
SL and SL/IM groups were associated with higher numbers 
of vagina-associated mgp41-specific IgA ASC in these groups 
compared to IM immunization (SL: 7 ±  3 gp41-specific IgA 
ASC; SL/IM: 8 ±  2 gp41-specific IgA ASC; IM: 4 ±  2 gp41-
specific IgA ASC).
FigUre 4 | sublingual (sl) priming increases mgp41-specific antibody responses in vaginal and rectal fluids. Macaques were immunized according to 
the study design detailed in Figure 2c. SL referred to group 1, SL/IM to group 2, and IM to group 3. IgG (a,c) and IgA (B,D) antibodies specific for mgp41 were 
detected in vaginal (a,B) and rectal fluids (c,D) obtained from individual macaques at the indicated time points. (a–D) Graphs represent the geometric means of 
endpoint titers measured at indicated time points for each immunization group. * in graphs denotes statistical differences between SL/IM group and IM group with 
p < 0.05 using the non-parametric Mann–Whitney U-test.
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combined sl/iM immunization increases 
the Frequency and Persistence of B cell 
responses
To further analyze the antibody responses induced after SL and 
SL/IM immunizations compared to IM immunization, the fre-
quency of circulating mgp41-specific ASC of IgG and IgA isotypes 
was determined 5  days postimmunization after priming (W9), 
boost (W21), and third IM immunizations (W29 only for IM 
group) (Figure 5). Variable numbers of mgp41-specific IgG ASC 
between macaques of a same group were detected after the prim-
ing with no significant differences between groups. The macaques 
from IM group had significantly higher numbers of circulating 
IgG ASC after the third IM immunization (week 29) compared 
to the other groups (Figure 5A), which can be explained by the 
increased bioavailability of the antigen after IM immunization. 
In contrast, both SL and SL/IM immunizations induced higher 
numbers of mgp41-specific IgA ASC after the last immunization 
compared to the IM group (Figure 5B), confirming in macaques 
the importance of the route of immunization to induce antibody 
responses of IgA isotype.
To further evaluate the persistence of the gp41-specific 
responses generated by the SL mgp41-CTB vaccine, circulating 
gp41-specific ASC were also quantified 1 month and 3 months 
after the last immunization after in  vitro stimulation in order 
to enumerate antigen-specific memory B cells. As shown in 
Figure  6A, the macaques of the IM group had significantly 
higher numbers of circulating IgG ASC 3 months after the third 
IM immunization compared to other groups (Figure  6A). In 
contrast, there seemed to be a trend toward higher numbers 
of mgp41-specific ASC of IgA isotype 1  month after SL/IM 
immunization compared to IM immunization as indicated by 
a p-Value of 0.08 using the non-parametric Mann–Whitney 
U-test (Figure 6B), consistent with the observation that SL/IM 
immunization, but not IM immunization generated mucosal 
gp41-specific IgA antibodies (Figure 4). We also determined the 
FigUre 5 | combined sl/iM immunization increases the numbers of circulating mgp41-specific iga antibody-secreting cells (ascs). Macaques were 
immunized according to the study design detailed in Figure 2c. SL referred to group 1, SL/IM to group 2, and IM to group 3. Peripheral blood mononuclear cells 
(PBMCs) were prepared from blood of individual macaques collected 5 days after priming immunizations (W9) and boost immunizations (W21 or W29 for group 3). 
Frequency of circulating mgp41-specific ASC of IgG and IgA isotypes was obtained by B ELISPOT assay. Results are represented in boxes and whiskers as 
individual numbers of mgp41-specific ASC of IgG (a) and IgA (B) isotypes and as the median value of gp41-specific spot numbers per million PBMC at the 
indicated time points for each immunization group (n = 6). * and ** in graphs denote statistical differences with p < 0.05 and p < 0.01, respectively, using the 
non-parametric Mann–Whitney U-test.
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frequency of total CD20+CD27+ IgD− memory B cells in the blood 
and BM at the end of the protocol by flow cytometric analysis. 
SL and combined SL/IM immunizations strongly increased the 
frequency of memory B cells both in blood and BM compared to 
IM immunization (Figures 6C,D).
Altogether, these data indicated that the SL immuniza-
tion increases the frequency and the duration of IgA antibody 
responses.
combined sl/iM increases the 
neutralizing activity of antibodies
To further evaluate the functional characteristics of the antibodies 
produced by SL immunization compared to antibodies generated 
after IM immunization, we determined their neutralizing activity 
against clade B virus primary isolates. The neutralizing activity of 
sera was performed using a TZM-bl assay with the QHO692.42 
virus primary isolate, a clade B transmitted founder virus classified 
as Tier 2. Sera collected 2 weeks (W22) and 3 months (W32 for SL 
and SL/IM groups and W40 for IM group) after the last immu-
nization were tested at several dilutions. Pre-immune sera from 
each macaque were used as control (Figure 7). Dose–response 
curves indicated that a modest but antigen-specific neutralizing 
activity was detected in the three immunization groups at week 
22 compared to pre-immune samples (Figure 7A). Interestingly, 
immune sera from SL and SL/IM immunization groups had per-
sistent neutralizing activity 3 months postimmunization contrary 
to the IM group. Analysis of the sera of individual macaques 
at the lowest dilution confirmed that the SL priming with the 
mgp41-CTB antigen improved the functional characteristics of 
the antibodies produced (Figure 7B). These data indicated that 
the SL immunization favors the generation and persistence of 
functional antibodies.
DiscUssiOn
The SL vaccination is attractive against mucosal infections 
including heterosexual transmission of HIV as recently explored 
in mouse models (8). The current report demonstrates in 
non-human primates that SL priming immunization followed 
by IM boost with a modified gp41-based vaccine increased 
antigen-specific serum IgG, mucosal IgG and IgA responses and 
frequency and duration of antigen-specific ASC of IgA isotype. 
Interestingly, macaques that received a combined mucosal-
systemic immunization exhibited functional antibodies 3 months 
after immunization whereas macaques immunized only by IM 
route did not. The present data highlight the efficacy of the SL 
immunization to generate mucosal antibody responses in non-
human primates.
We designed a mutated gp41 polypeptide with increased 
solubility to improve the synthesis process of the vaccine as well 
as its accessibility to the immune system. The destabilization of 
the gp41 six-helix bundle structure with mutations allowed the 
exposure of hidden gp41 epitopes, known to be accessible during 
virus fusion (33, 34). Moreover, induction by vaccination of HIV 
broadly neutralizing antibodies (bnAb), such as 2F5, was shown 
to be difficult due to their autoreactivity with self-antigens lead-
ing to immune tolerance (35). Besides, generation of a 2F5-like 
neutralizing response was described to be dependent on the mem-
brane environment, which is not the aim of our antigen design 
(36). Therefore, the point mutation of the immunodominant 
FigUre 6 | sublingual (sl) immunization induces persistent gp41-specific iga antibody responses and increased memory B cells. (a,B) Peripheral 
blood mononuclear cells (PBMCs) collected 4 weeks (W24 for SL and SL/IM groups and W32 for IM group) and 3 months after the last immunization (W32 for 
group 1 and 2 and W40 for group 3) were stimulated in vitro as described in Section “Materials and Methods.” The frequency of circulating mgp41-specific 
antibody-secreting cell of IgG (a) and IgA (B) isotypes was measured by B ELISPOT assay. Results are expressed as individual values in boxes and whiskers with 
median values for each immunization group. * and ** in graphs denote statistical differences with p < 0.05 and p < 0.005, respectively, using the non-parametric 
Mann–Whitney U-test. (c,D) The frequency of total CD27+IgD− memory B cells among CD20+ B cells was assessed by flow cytometry in blood (c) and bone 
marrow cells (D) of individual macaques at the end of the protocol according to the gating strategy shown in Figure S2 in Supplementary Material. Results are 
represented as percentages of CD27+IgD− memory B cells among CD20+ B cells. * and ** in graphs denote statistical differences with p < 0.05 and p < 0.005, 
respectively, using the non-parametric Mann–Whitney U-test.
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ELDKWA epitope recognized by the bnAb 2F5 was designed to 
favor the generation of other functional antibodies.
Not only the vaccine design but also the route of immunization 
are critical to generate the right immunity at the right site (37, 
38). We previously reported that the SL application of antigens 
with CT in mice induced mucosal antibodies and CTL in the 
systemic compartment, in the upper aerodigestive tract, in the 
lung mucosa (39), and in the genital tract (11, 16). The present 
study extends these observations to female macaques.
The present data further indicate that the antibodies produced 
are functional and exhibit modest neutralizing activity against 
the Tier 2 virus QH0692.42, which is difficult to neutralize. 
Antibodies with HIV-blocking transcytosis activity, FcγR-
mediated inhibition capacity or antibody-dependent cellular 
cytotoxicity (ADCC) were recently described to contribute to 
the protection against HIV infection (17, 40). Further studies 
are needed to evaluate whether the antibodies produced by the 
current SL vaccine display additional HIV-blocking inhibitory 
activity such as ADCC or decreased infectivity potential by 
aggregation. These latter inhibitory effects would be particularly 
valuable to protect against HIV-1 mucosal transmission (41).
Combined IM/intranasal vaccination in rhesus macaques 
with another gp41-based vaccine was shown to induce mucosal 
antibodies and protection against SHIV vaginal challenges (17). 
Moreover, SL priming immunization with a replicating adenovi-
rus followed by an IM boost was shown to induce mucosal IgA 
antibodies and delayed viremia against rectal challenges with 
SIVmac251 in rhesus macaques (42). The present data showing that 
SL priming with a non-replicative vaccine improved the genera-
tion of mucosal antibodies, especially mucosal IgA, extend these 
FigUre 7 | neutralizing activity of the sera from immune macaques. (a,B) The human immunodeficiency virus neutralizing activity was performed using 
pre-immune (W-1) and immune sera 2 weeks after the fifth immunization (W22 for all groups) or 3 months after the last immunization (W32 for SL and SL/IM groups, 
W40 for IM group). The neutralizing activity of immune sera and control sera was performed using a TZM-bl assay and QHO692.42 clade B virus primary isolate. 
(a) Dose–response curve of neutralizing activity of serial dilutions of individual immune sera collected W22 (hatched black bars), W32 or W40 (black bars) were 
compared to pre-immune sera from the same macaques (gray bars). Bars indicate mean values of the percentage of reduction in infection compared to the 
reference control without serum + SD. (B) Individual neutralizing activity of sera from individual macaques tested at a dilution of 1/16. The results are represented 
as individual values and mean values for each group. Neutralizing activities were measured twice in independent experiments for each sample. The hatched line 
indicates a neutralizing activity with IC50. * and ** denote statistical differences between pre-immune sera (W-1) and immune sera (W22, W32) of a same 
immunization group using the non-parametric Mann–Whitney U-test, *p < 0.05 and **p < 0.005; ns, no statistical difference.
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observations. Several studies in highly exposed, persistently 
HIV-1 seronegative (HEPS) female sex workers have shown the 
presence of mucosal IgA against gp41 in their genital tract (7, 
43). Even detected at low levels, purified IgA antibodies from 
such HEPS volunteers showed neutralizing activity (44, 45). In 
our study, the SL and combined immunizations, but not the IM 
immunization, induced antigen-specific mucosal IgA antibodies 
and IgA-secreting cells. The protective efficacy of such antibodies 
against viral challenge in macaques remains to be established. If 
efficient, such a SL vaccine would avoid the potential danger of 
nasal immunization, which is the passage of antigen through the 
blood–brain barrier.
Repeated SL immunizations did not increase antibody titers, 
but just maintained their levels. This suggests that monthly SL 
immunizations do not amplify the B cell response but rather 
induce the maturation and functionality of antigen-specific B cell 
clones as shown after oral (46) and systemic immunizations (47).
The CTB delivery vector used in the present study favors the 
mucosal delivery of antigens after SL and intravaginal immuniza-
tions (21, 48). The SL administration in healthy female volunteers 
of the licensed quadrivalent HPV vaccine (Gardasil®) without 
any known mucoadhesive properties failed to induce systemic 
and mucosal antibodies contrary to the IM route, which may 
be explained by the lack of appropriate delivery system for SL 
immunization (49). Nevertheless, in the present study, the het-
erogeneity in antibody responses between macaques immunized 
by the SL route could reflect an inconsistent mucosal uptake of 
the vaccine due to its dilution by the saliva of certain macaques. 
Semi-solid formulations of SL vaccines could certainly 
improve antigen absorption and immune responses. Such solid 
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formulations could be based on patches, pastilles, or gels that 
have been recently developed for SL administration of drugs (50, 
51). Future SL vaccines might also target local antigen-presenting 
cells. In fact, the macaque SL mucosa is an immunocompetent 
tissue containing DCs. SL DCs were shown to be key antigen-
presenting cells in mice with enhanced migratory properties 
contributing to genital immunity (48). Altogether, this suggests 
that an optimized formulation and the targeting of SL DCs in 
macaques and humans could improve sublingually induced 
mucosal immune responses.
In conclusion, such combined SL/IM vaccine strategy improves 
the quality of the antibodies generated and suggests that the SL/
IM vaccination with appropriate formulations of antigens could 
help to block heterosexual transmission of HIV by increasing B 
cell immune responses in mucosal tissues.
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